Emergent BioSolutions
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 1.6K
- Market Cap
- -
- Introduction
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.
Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 44
- Registration Number
- NCT05935917
- Locations
- 🇺🇸
Altasciences, Overland Park, Kansas, United States
Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults
- Conditions
- Opioid Overdose
- Interventions
- Combination Product: 16 mg naloxone AP003Combination Product: 8 mg naloxone NARCAN Nasal Spray
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 24
- Registration Number
- NCT05377255
- Locations
- 🇺🇸
Syneos Health Clinical Research Services, Miami, Florida, United States
Study of SIAN Nasal Spray in Healthy Adults
- Conditions
- Cyanide Poisoning
- Interventions
- Drug: Stabilized Isoamyl Nitrite (SIAN)
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 47
- Registration Number
- NCT05194358
- Locations
- 🇺🇸
Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States
🇺🇸Austin Clinical Research Unit - PPD Phase I Clinic, Austin, Texas, United States
Universal Influenza A Vaccine in Healthy Adults
- Conditions
- Human Influenza
- Interventions
- Biological: UFluA 60 µg each antigen/doseBiological: PlaceboBiological: UFluA 20 µg each antigen/dose
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 27
- Registration Number
- NCT05155319
- Locations
- 🇦🇺
Northern Beaches Clinical Research, Brookvale, New South Wales, Australia
🇦🇺Linear Clinical Research, Nedlands, Western Australia, Australia
A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 23
- Registration Number
- NCT05142306
- Locations
- 🇺🇸
Qps-Mra, Llc, Miami, Florida, United States
🇺🇸Bio-Kinetic Clinical Applications, LLC, Springfield, Missouri, United States
A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 28
- Registration Number
- NCT04661839
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study
- Conditions
- Anthrax
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 210
- Registration Number
- NCT04067011
- Locations
- 🇺🇸
Avail Clinical Research, LLC, DeLand, Florida, United States
🇺🇸The Center for Pharmaceutical Research, Kansas City, Missouri, United States
🇺🇸Meridian Clinical Research, LLC, Omaha, Nebraska, United States
VELOCITY: An Anthrax Vaccine Clinical Study
- Conditions
- Anthrax
- Interventions
- Biological: AV7909Biological: BioThrax
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 3862
- Registration Number
- NCT03877926
- Locations
- 🇺🇸
Achieve Clinical Research, LLC, Birmingham, Alabama, United States
🇺🇸Optimal Research, LLC, Rockville, Maryland, United States
🇺🇸Coastal Clinical Research, an AMR company, Mobile, Alabama, United States
Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)
- Conditions
- Zika Virus InfectionZika Virus Disease
- Interventions
- Biological: Zika Virus Immune Globulin (ZIKV-IG)Other: Placebo
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 30
- Registration Number
- NCT03624946
- Locations
- 🇨🇦
Syneos Health, Early Phase, Toronto, Ontario, Canada
Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 10
- Registration Number
- NCT03569514